The controlled RSV infection model
beReady: the fast track to vaccine research
beReady includes a general clinical vaccine protocol and a consent procedure that are approved by the regulatory authority. The beReady protocol allows us to maintain a pre-screened pool of dedicated healthy volunteers, ready at a moment’s notice to be enrolled and dosed in a clinical study with a new vaccine. With this fast-track approach, the only additional approval required before study commencement concerns vaccine-specific documentation, which additionally benefits from an expedited review process by the Dutch competent authority. Thanks to our partnerships with expert laboratories, we are also able to ensure rapid setup and turnaround times for viral screens. Overall, this approach promises significant reductions in the time needed to test vaccines for emerging infectious diseases, meaning that a vaccine trial can start in as little as three weeks.